The 3 most recent market catalysts affecting $GPCR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data
Structure Therapeutics (GPCR) reported positive early-stage data for ACCG-2671, showing a 3.3% mean body weight reduction at Day 24, and extended data for aleniglipron, demonstrati…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Structure Therapeutics Says Aleniglipron Achieved Up To 16.2% Weight Loss At 72 Weeks In ACCESS Open-Label Extension With No Plateau; Says Phase 1/2a ACCG-2671 SAD Trial Showed 3.3% Weight Loss
This headline represents a significant positive catalyst for Structure Therapeutics (GPCR) due to the impressive and sustained weight loss data for Aleniglipron. The 'no plateau' a…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110
Citizens analyst Jonathan Wolleben has adjusted the price target for Structure Therapeutics (GPCR) from $113 to $110, a modest reduction of approximately 2.6%. Despite this, the 'M…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.